REFERENCE
Decision Resources.Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017. Media Release: 11 Mar 2009. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
The use of bevacizumab [Avastin] and cetuximab [Erbitux] will drive the colorectal cancer market to grow by almost $1 billion in 2017. Pharmacoecon. Outcomes News 574, 11 (2009). https://doi.org/10.2165/00151234-200905740-00028
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905740-00028